{"entity":{"id":"caroline-robert","kind":"person","name":"Caroline Robert","aka":[],"tldr":"Led KEYNOTE-006 and COMBI-v, the trials that made pembrolizumab and dabrafenib-trametinib standards in melanoma.","summary":"Caroline Robert was principal investigator of KEYNOTE-006, which showed pembrolizumab beats ipilimumab in advanced melanoma and established PD-1 monotherapy, of CheckMate 066 (nivolumab versus chemotherapy) and of COMBI-v (dabrafenib plus trametinib versus vemurafenib). She has led long-term follow-up analyses defining durable remission after stopping immunotherapy and heads dermato-oncology at Gustave Roussy.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Robert%20C%5BAuthor%5D%20melanoma%20pembrolizumab"}],"tags":["melanoma","immunotherapy","trialist"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors"],"targets":["pd1","braf"],"drugs":["pembrolizumab","nivolumab","ipilimumab"],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":["keynote-006"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Dermatology Unit, Gustave Roussy; Professor, Paris-Saclay University","institutionId":"gustave-roussy","specialisms":["Melanoma","Immunotherapy","BRAF/MEK targeted therapy","Dermato-oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Robert%20C%5BAuthor%5D%20melanoma%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1503093"},{"title":"Improved overall survival in melanoma with combined dabrafenib and trametinib (COMBI-v)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1412690"},{"title":"Nivolumab in previously untreated melanoma without BRAF mutation (CheckMate 066)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1412082"}],"orcid":"0000-0002-9493-0238"},"route":"/people/caroline-robert/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"}],"trial":[{"id":"keynote-006","kind":"trial","name":"KEYNOTE-006","route":"/trials/keynote-006/"}],"paper":[{"id":"paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015","kind":"paper","name":"KEYNOTE-006 (Robert 2015): pembrolizumab versus ipilimumab in advanced melanoma","route":"/key-papers/paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015/"}]}}